Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4697-4702

  Chou, Sunwen ^a,b   Ercolani, Ronald J ^b   Sahoo, Malaya K ^c   Lefterova, Martina I ^c   Strasfeld, Lynne M ^a   Pinsky, Benjamin A ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CYTOSINE; DNA DIRECTED DNA POLYMERASE; FOSCARNET; GANCICLOVIR; PHOSPHONIC ACID DERIVATIVE; UL54 PROTEIN, HUMAN HERPESVIRUS 5; VIRUS PROTEIN;

ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CASE REPORT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PNEUMONIA, VIRAL; TIME; VIROLOGY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FOSCARNET; GANCICLOVIR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; PNEUMONIA, VIRAL; TIME FACTORS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84905397138     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03214-14     Document Type: Article

References (17)

1. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A. 2013. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantatio. 96:333-360. http://dx.doi.org/10.1097/TP.0b013e31829df29d.
2. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712. http://dx.doi.org/10.1128/ CMR.00009-10.
3. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. 1999. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 37:2291-2296.
4. Gorzer I, Guelly C, Trajanoski S, Puchhammer-Stockl E. 2010. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J. Virol. 84:7195-7203. http://dx.doi.org/10. 1128/JVI.00475-10.
5. Renzette N, Gibson L, Bhattacharjee B, Fisher D, Schleiss MR, Jensen JD, Kowalik TF. 2013. Rapid intrahost evolution of human cytomegalovirus is shaped by demography and positive selection. PLoS Genet. 9:e1003735. http://dx.doi.org/10.1371/journal.pgen.1003735.
6. Sahoo MK, Lefterova MI, Yamamoto F, Waggoner JJ, Chou S, Holmes SP, Anderson MW, Pinsky BA. 2013. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J. Clin. Microbiol. 51:3700-3710. http://dx.doi.org/10.1128/JCM.01605-13.
7. Hong KM, Najjar H, Hawley M, Press RD. 2004. Quantitative real-time PCR with automated sample preparation for diagnosis and monitoring of cytomegalovirus infection in bone marrow transplant patients. Clin. Chem. 50:846-856. http://dx.doi.org/10.1373/clinchem.2003.026484.
8. Chou S. 2011. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. J. Clin. Virol. 50:287-291. http://dx.doi.org/10.1016/j.jcv.2011.01.004.
9. Baldanti F, Underwood MR, Talarico CL, Simoncini L, Sarasini A, Biron KK, Gerna G. 1998. The Cys607→Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob. Agents Chemother. 42:444-446.
10. Chou S, Van Wechel LC, Lichy HM, Marousek GI. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49:2710-2715. http://dx.doi.org/10.1128/AAC.49.7.2710-2715.2005.
11. Mousavi-Jazi M, Schloss L, Wahren B, Brytting M. 2003. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase. J. Clin. Virol. 26:301-306. http://dx.doi.org/10.1016/S1386-6532(02)00046-X.
12. Mylonakis E, Kallas WM, Fishman JA. 2002. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin. Infect. Dis. 34:1337-1341. http://dx.doi.org/10.1086/340101.
13. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhauser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kolling K, Stobernack HP, Lischka P, Zimmermann H, Rubsamen-Schaeff H, Champlin RE, Ehninger G. 2014. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N. Engl. J. Med. 370:1781-1789. http://dx.doi.org/10.1056/ NEJMoa1309533.
14. Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. 2014. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob. Agents Chemother. 58:610-613. http://dx.doi.org/10.1128/AAC.01794-13.
15. Chou S, Boivin G, Ives J, Elston R. 2014. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. J. Infect. Dis. 209:1219-1226. http://dx.doi.org/10.1093/infdis/jit654.
16. Chou S, Marousek GI. 2008. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J. Virol. 82:246-253. http://dx.doi.org/10.1128/JVI.01787-07.
17. Chou S, Ercolani RJ, Marousek G, Bowlin TL. 2013. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multi-drug resistance. Antimicrob. Agents Chemother. 57:3375-3379. http://dx.doi.org/10.1128/AAC.00511-13